The PPAR Pocket: Renewed Opportunities for Drug Development

Overview

Journal PPAR Res

Publisher Wiley

Date 2020 Jul 23

PMID 32695150

Citations 7

Authors

Asmund Kaupang

Trond Vidar Hansen

Affiliations

Soon will be listed here.

Abstract

The past decade of PPAR research has dramatically improved our understanding of the structural and mechanistic bases for the diverging physiological effects of different classes of PPAR ligands. The discoveries that lie at the heart of these developments have enabled the design of a new class of PPAR ligands, capable of isolating central therapeutic effects of PPAR modulation, while displaying markedly lower toxicities than previous generations of PPAR ligands. This review examines the emerging framework around the design of these ligands and seeks to unite its principles with the development of new classes of ligands for PPAR and PPAR. The focus is on the relationships between the binding modes of ligands, their influence on PPAR posttranslational modifications, and gene expression patterns. Specifically, we encourage the design and study of ligands that primarily bind to the pockets of PPAR and PPAR. In support of this development, we highlight already reported ligands that if studied in the context of this new framework may further our understanding of the gene programs regulated by PPAR and PPAR. Moreover, recently developed pharmacological tools that can be utilized in the search for ligands with new binding modes are also presented.

Citing Articles

The Peroxisome Proliferator-Activated Receptors of Ray-Finned Fish: Unique Structures, Elusive Functions.

Boukouvala E, Krey G Biomolecules. 2024; 14(6).

PMID: 38927038 PMC: 11201486. DOI: 10.3390/biom14060634.

Naringenin and β-carotene convert human white adipocytes to a beige phenotype and elevate hormone- stimulated lipolysis.

Coulter A, Greenway F, Zhang D, Ghosh S, Coulter C, James S Front Endocrinol (Lausanne). 2023; 14():1148954.

PMID: 37143734 PMC: 10153092. DOI: 10.3389/fendo.2023.1148954.

New High-Throughput Screen Discovers Novel Ligands of Full-Length Nuclear Receptor LRH-1.

Malabanan M, Chapagain P, Haratipour Z, Choi W, Orun A, Blind R ACS Chem Biol. 2023; 18(5):1101-1114.

PMID: 37074920 PMC: 10404069. DOI: 10.1021/acschembio.2c00805.

Anti-Obesity and Anti-Inflammatory Effects of Novel Carvacrol Derivatives on 3T3-L1 and WJ-MSCs Cells.

Cacciatore I, Spalletta S, Di Rienzo A, Flati V, Fornasari E, Pierdomenico L Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986440 PMC: 10055808. DOI: 10.3390/ph16030340.

PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo.

Sha Y, Wu J, Paul B, Zhao Y, Mathews P, Li Z Cancer Lett. 2022; 545:215832.

PMID: 35872263 PMC: 10355274. DOI: 10.1016/j.canlet.2022.215832.

References

Bruning J, Chalmers M, Prasad S, Busby S, Kamenecka T, He Y . Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure. 2007; 15(10):1258-71. DOI: 10.1016/j.str.2007.07.014. View

Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris T . Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature. 2008; 456(7220):350-6. PMC: 2743566. DOI: 10.1038/nature07413. View

Motani A, Wang Z, Weiszmann J, McGee L, Lee G, Liu Q . INT131: a selective modulator of PPAR gamma. J Mol Biol. 2009; 386(5):1301-11. DOI: 10.1016/j.jmb.2009.01.025. View

Higgins L, Mantzoros C . The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer. PPAR Res. 2008; 2008:936906. PMC: 2522386. DOI: 10.1155/2008/936906. View

Liberato M, Nascimento A, Ayers S, Lin J, Cvoro A, Silveira R . Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists. PLoS One. 2012; 7(5):e36297. PMC: 3359336. DOI: 10.1371/journal.pone.0036297. View

Kojetin D, Matta-Camacho E, Hughes T, Srinivasan S, Nwachukwu J, Cavett V . Structural mechanism for signal transduction in RXR nuclear receptor heterodimers. Nat Commun. 2015; 6:8013. PMC: 4547401. DOI: 10.1038/ncomms9013. View

Rastinejad F, Ollendorff V, Polikarpov I . Nuclear receptor full-length architectures: confronting myth and illusion with high resolution. Trends Biochem Sci. 2014; 40(1):16-24. PMC: 4274238. DOI: 10.1016/j.tibs.2014.10.011. View

Liu Z, Cao J, Gao X, Zhou Y, Wen L, Yang X . CPLA 1.0: an integrated database of protein lysine acetylation. Nucleic Acids Res. 2010; 39(Database issue):D1029-34. PMC: 3013790. DOI: 10.1093/nar/gkq939. View

Hughes T, Giri P, de Vera I, Marciano D, Kuruvilla D, Shin Y . An alternate binding site for PPARγ ligands. Nat Commun. 2014; 5:3571. PMC: 4070320. DOI: 10.1038/ncomms4571. View

10.

Prueksaritanont T, Gorham L, Ma B, Liu L, Yu X, Zhao J . In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997; 25(10):1191-9. View

11.

Christensen L, El-Houri R . Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds. Molecules. 2018; 23(10). PMC: 6222920. DOI: 10.3390/molecules23102431. View

12.

Li Y, Zhang J, Schopfer F, Martynowski D, Garcia-Barrio M, Kovach A . Molecular recognition of nitrated fatty acids by PPAR gamma. Nat Struct Mol Biol. 2008; 15(8):865-7. PMC: 2538624. DOI: 10.1038/nsmb.1447. View

13.

Dowell P, Ishmael J, Avram D, PETERSON V, Nevrivy D, Leid M . Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein. J Biol Chem. 1999; 274(22):15901-7. DOI: 10.1074/jbc.274.22.15901. View

14.

Glass C, Rosenfeld M . The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000; 14(2):121-41. View

15.

Liu Z, Wang Y, Gao T, Pan Z, Cheng H, Yang Q . CPLM: a database of protein lysine modifications. Nucleic Acids Res. 2013; 42(Database issue):D531-6. PMC: 3964993. DOI: 10.1093/nar/gkt1093. View

16.

Ammazzalorso A, DAngelo A, Giancristofaro A, De Filippis B, Di Matteo M, Fantacuzzi M . Fibrate-derived N-(methylsulfonyl)amides with antagonistic properties on PPARα. Eur J Med Chem. 2012; 58:317-22. DOI: 10.1016/j.ejmech.2012.10.019. View

17.

Waku T, Shiraki T, Oyama T, Morikawa K . Atomic structure of mutant PPARgamma LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARgamma/RXRalpha function by covalently bound ligands. FEBS Lett. 2008; 583(2):320-4. DOI: 10.1016/j.febslet.2008.12.017. View

18.

Marciano D, Kuruvilla D, Boregowda S, Asteian A, Hughes T, Garcia-Ordonez R . Pharmacological repression of PPARγ promotes osteogenesis. Nat Commun. 2015; 6:7443. PMC: 4471882. DOI: 10.1038/ncomms8443. View

19.

Salim C, Boxberg Y, Alterio J, Fereol S, Nothias F . The giant protein AHNAK involved in morphogenesis and laminin substrate adhesion of myelinating Schwann cells. Glia. 2008; 57(5):535-49. DOI: 10.1002/glia.20782. View

20.

Adhikary T, Kaddatz K, Finkernagel F, Schonbauer A, Meissner W, Scharfe M . Genomewide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). PLoS One. 2011; 6(1):e16344. PMC: 3023804. DOI: 10.1371/journal.pone.0016344. View